@FiercePharma: More tit-for-tat in Vivus proxy fight: FMC sues over meeting delay. $VVUS didn't like scoreboard, says Colin. Story | Follow @FiercePharma
@EricPFierce: FDA says Cispharma didn't do enough to make sure blood tissue didn't get into drugs when worker injured. Article | Follow @EricPFierce
@CarlyHFierce: NICE nixes Pfizer's CML drug Bosulif. Article | Follow @CarlyHFierce
> Abbott Laboratories ($ABT) posted a 72% drop in profits for the second quarter, partially because of the spinoff of its AbbVie ($ABBV) pharmaceuticals business in January. Report
> In the long-running fight over Teva Pharmaceutical Industries' ($TEVA) patent on its top-selling Copaxone drug, a U.S. judge tossed out infringement claims against Mylan ($MYL), partially clearing the way for generics. Report
> GlaxoSmithKline ($GSK) CEO Andrew Witty will step down as lead independent director on a U.K. government board at the end of his term, the company said, adding that the move is unrelated to bribery allegations GSK faces in China. Report
> Indian drugmakers Cipla and Alembic reportedly are challenging the government's new drug-price controls, citing provisions requiring companies to pull existing stocks within 45 days. Report
> The FDA said the manufacturer of two popular sports supplements, Dallas-based USPlabs, volutarily destroyed its stock of the products. Report
@FierceMedDev: Popular yesterday: For J&J, no device growth without Synthes. Article | Follow @FierceMedDev
@MarkHFierce: The device tax has already cost the industry $1 billion. Editor's corner | Follow @MarkHFierce
@DamianFierce: Will all that M&A help Abbott turn its medical device sales around? More | Follow @DamianFierce
> St. Jude's Q2 produces mixed results, but CEO asserts progress. Story
> Abbott's device sales sag, but M&A could brighten the future. More
> Medical device ID plan faces delays. Item
Biotech News
@FierceBiotech: Popular: Is this the NIH Francis Collins wanted to create? Editor's corner | Follow @FierceBiotech
@JohnCFierce: GSK China official: We inflated conference costs, handed out bribes, pocketed cash and upped drug prices. More | Follow @JohnCFierce
@RyanMFierce: Bioinformatics buy bolsters Life's diagnostics pact with Merck Serono. Report | Follow @RyanMFierce
@EmilyMFierce: Animal studies produce many false positives. More | Follow @EmilyMFierce
> Buzz: Pfizer prowls Onyx auction block as bidding looms. Report
> Sequella scouts $38M round after nabbing Pfizer antibiotic. Article
> Lundbeck, Otsuka tout improved cognition in mid-stage Alzheimer's study. More
Drug Delivery News
@MichaelGFierce: Rexahn snags nanotech platform for cancer drug delivery. Article | Follow @MichaelGFierce
> CalTech team combines two breast cancer drugs using nanoparticles. Report
> Math models tailor drug delivery using patient DNA. Story
> Melbourne team concocts self-assembling, nanoengineered drug delivery tech. Article
> York students eye crowdfunding for nanoparticle cancer patch treatment work. Item
> Oramed raising $4.6M for oral insulin trial. News
And Finally... Studies find that a predicted decline in dementia rates, because of education and health improvements, has proven true. Report